New insights in statins affecting atheromatous plaque macrophages. Issue 4 (August 2021)

• Record Type: Journal Article
• Authors: Härdtner, Carmen; Ehlert, Carolin A.; Hilgendorf, Ingo
• Is Part Of: Current opinion in lipidology. Volume 32:Issue 4(2021)
• Publication Date: 2021-08
• Subjects: atherosclerosis -- cholesterol -- macrophages -- small GTPases -- statins; Lipids -- Periodicals; 572.574
• DOI: 10.1097/MOL.0000000000000769
• Languages: English
• ISSNs: 1473-6535

Abstract

Abstract : Purpose of review: Macrophages are key protagonists of atherosclerotic plaque development and hence represent targets of therapeutic intervention. Statins are the most potent widely used atheroprotective drugs. Therefore, whether and how statins influence atheromatous plaque macrophages has remained at the center of cardiovascular research for decades. Recent findings: Because statins are capable of regulating macrophage functions in cell culture, largely independent of their cholesterol-lowering effect, it was assumed that these pleiotropic effects operate in vivo as well. Recent experimental data, in line with clinical observations, indicate, however, that statins do not interact with macrophages in atherosclerotic plaques, directly, and instead control their functions and assembly indirectly via changes to circulating lipid levels and endothelial activation. Summary: Statin-mediated lipid lowering induces plaque regression which is characterized by a decline in plaque macrophage content. Understanding how statins provoke this protective phenotype may inspire conceptually new therapeutic approaches in cardiovascular medicine.